Cellectis S.A. (CLLS)

NASDAQ: CLLS · IEX Real-Time Price · USD
6.99 -0.31 (-4.18%)
Jan 18, 2022 1:50 PM EST - Market open
Market Cap317.64M
Revenue (ttm)81.55M
Net Income (ttm)-151.38M
Shares Out45.48M
EPS (ttm)-2.92
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume137,199
Open7.13
Previous Close7.29
Day's Range6.91 - 7.24
52-Week Range6.91 - 34.71
Beta2.19
AnalystsBuy
Price Target26.44 (+278.6%)
Earnings DateNov 4, 2021

About CLLS

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 ...

IndustryBiotechnology
IPO DateFeb 7, 2007
CEOAndre Choulika
Employees272
Stock ExchangeNASDAQ
Ticker SymbolCLLS
Full Company Profile

Financial Performance

Financial numbers in millions EURFinancial Statements

Analyst Forecast

According to 11 analysts, the average rating for Cellectis stock is "Buy." The 12-month stock price forecast is 26.44, which is an increase of 278.59% from the latest price.

Price Target
$26.44
(278.59% upside)
Analyst Consensus: Buy

News

Cellectis' Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials

• Allogene reported that Chromosomal Abnormality Was Not the Result of TALEN® Gene Editing or Allogene's Manufacturing Process

1 week ago - GlobeNewsWire

Cellectis Provides Business Objectives for 2022 and Updates its Corporate Presentation

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving ce...

1 week ago - GlobeNewsWire

Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leu...

NEW YORK, Dec. 11, 2021 (GLOBE NEWSWIRE) -- Cellectis  (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company employing its pioneering TALEN® gene-editing platform to develop in...

1 month ago - GlobeNewsWire

Cytovia, Cellectis Expand Collaboration On Gene-Edited Cancer Platform In China

Cytovia Therapeutics Inc and Cellectis SA (NASDAQ: CLLS) have expanded their collaboration of TALEN gene-edited iPSC-derived NK and CAR-NK cells. The expanded agreement will include a new CAR target and...

1 month ago - Benzinga

Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable Broader Collaboration in China

Cytovia Commits to Additional Milestones and Equity grant Cytovia Commits to Additional Milestones and Equity grant

1 month ago - GlobeNewsWire

Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Product Candidate Targeting Mesothel...

NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage gene-editing company employing its core technology to develop product...

2 months ago - GlobeNewsWire

Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2021

•   Sponsored programs at ASH 2021 - preliminary clinical data to be presented at ASH 2021 for product candidate UCART22 and preclinical data from Cellectis gene therapy product candidate TALGlobin01

2 months ago - GlobeNewsWire

Cellectis Announces Release of Abstracts at ASH Showcasing Updated Preliminary Clinical Data from BALLI-01 Study and ...

NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing company with clinical-stage immuno-oncology programs using allogeneic c...

2 months ago - GlobeNewsWire

Cellectis to Hold Third Quarter Earnings Call on Friday, November 5, 2021 at 8AM EDT

NEW YORK, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using all...

2 months ago - GlobeNewsWire

Cellectis Presents Initial Preclinical Data on Two Novel Gene Therapies for Patients with RAG1 Severe Combined Immuno...

NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing company with clinical-stage immuno-oncology programs using allogeneic c...

2 months ago - GlobeNewsWire

Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of...

NEW YORK, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using all...

3 months ago - GlobeNewsWire

7 Gene Editing Stocks Promising to Change our DNA

Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market. The post 7 Gene Editing Stocks Promising to Change our DNA appeared fi...

4 months ago - InvestorPlace

Cellectis Announces Participation in Five Investor Conferences

NEW YORK, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using all...

4 months ago - GlobeNewsWire

Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2021

• Preliminary translational data validate UCARTCS1 as a promising potential therapy for relapsed orrefractory multiple myeloma patients.

5 months ago - GlobeNewsWire

Cellectis organise une conférence téléphonique pour présenter ses résultats financiers du deuxième trimestre 2021 le ...

NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ : CLLS – EURONEXT GROWTH : ALCLS) (la « Société »), une société d'édition du génome spécialisée dans les essais en immuno-oncologie en ...

5 months ago - GlobeNewsWire

Cellectis to Hold Second Quarter 2021 Earnings Call on Friday, August 6, 2021 at 8AM EDT

NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using all...

5 months ago - GlobeNewsWire

The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century

Doudna's breakthrough in CRISPR has since ushered in a new era of genetic engineering, making these the best gene-editing stocks to buy. The post The Top 7 Gene-Editing Stocks to Buy for the Biggest Sci...

6 months ago - InvestorPlace

Cellectis Unveils Four Additional Preclinical Candidates For Solid Tumors

Cellectis SA (NASDAQ: CLLS) has announced four new preclinical UCART product candidates targeting solid tumors - UCART20x22; the first allogeneic bi-specific CAR-T cell targeting B-cell malignancies, an...

7 months ago - Benzinga

Cellectis' Innovation Days event highlighted New Product Development, New Genome Surgery Platform .HEAL, and Manufact...

• Four new product candidates under pre-clinical development announced; UCART20x22; the first allogeneic bi-specific CAR-T cell targeting  B-cell malignancies, and three additional product candidates fo...

7 months ago - GlobeNewsWire

Cellectis S.A. Reports Results from Annual Shareholders' General Meeting Held on June 1, 2021

NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. held its Annual Shareholders' General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) on June 1, 2021 at its head office in Paris, France.

7 months ago - GlobeNewsWire

Cellectis and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-T

PARIS, May 11, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – Euronext Growth: ALCLS), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-c...

8 months ago - GlobeNewsWire

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2021

NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary technologies t...

8 months ago - GlobeNewsWire

Cellectis' Annual Shareholders' General Meeting to be Held on June 1, 2021

NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS).

8 months ago - GlobeNewsWire

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)

9 months ago - GlobeNewsWire

Cellectis Completes Sale of $47 million through its ATM program

NEW YORK, April 09, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary technologies...

9 months ago - GlobeNewsWire